Jazz Pharmaceuticals' tremor drug fails
to meet main goal in mid-stage study
Send a link to a friend
 [June 20, 2024]
(Reuters) -Jazz Pharmaceuticals said on Thursday its experimental
drug to treat a neurological condition that causes involuntary and
rhythmic shaking failed to meet the main goal in a mid-stage study.
Shares of Jazz fell about 4% to $108 in premarket trading.
While improvements were observed in patients who were treated with the
drug, suvecaltamide, these were not statistically significant, the
company said.
Jazz said it will further evaluate data from the study.
[to top of second column]
|
 It is testing the drug in a separate
study as a potential treatment for Parkinson's disease-related
tremors.
(Reporting by Mariam Sunny and Bhanvi Satija in Bengaluru; Editing
by Mrigank Dhaniwala)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
